At ASMS 2026, mass spectrometry stakes its claim Sessions spanning chemoproteomics, AI-driven proteomics, biotherapeutic characterization, single-cell omics, and spatial multiomics all pointed toward mass spectrometry’s growing role in drug discovery and development. Written byAndrea Corona

https://www.drugdiscoverynews.com/at-asms-2026-mass-spectrometry-stakes-its-claim-17280 The 74th annual conference on Mass Spectrometry and Allied Topics ran June 1–5 at the San Diego Convention Center, bringing together researchers across academia, industry, and government for four days of oral sessions, poster presentations, workshops, and exhibits. The program — spanning more than 40 concurrent oral sessions per day across topics from ion mobility instrumentation to clinical analysis, environmental contaminants, and cancer immunology — offered a cross-section of where mass spectrometry currently sits and where it is heading.

Patient-derived mini brains reveal mechanism and treatment for rare genetic disease Dehydrodolichyl diphosphate synthase (DHDSS)-related disease has no available treatments. The new work could finally change that with nicotinamide mononucleotide (NMN). Written byAllison Whitten, PhD

https://www.drugdiscoverynews.com/patient-derived-mini-brains-reveal-mechanism-and-treatment-for-rare-genetic-disease-17282 Last week at the annual conference of the European Society of Human Genetics in Gothenburg, Sweden, researchers presented work on the first cortical brain organoid models of dehydrodolichyl diphosphate synthase (DHDSS)-related disease — a condition with no current treatments. The pioneering work, led by Eva Morava and Tamas Kozicz's team at the Icahn School of Medicine at Mount Sinai, allowed the scientists to not only elucidate the mechanism of the disease, but also test out a widely available therapeutic — nicotinamide mononucleotide (NMN), better known as vitamin B3.

FDA approves sacituzumab govitecan-hziy as monotherapy and in combination with pembrolizumab for first-line treatment of triple-negative breast cancer

https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-sacituzumab-govitecan-hziy-monotherapy-and-combination-pembrolizumab-first-line?utm_medium=email&utm_source=govdelivery

At-home brain implant gives man with motor neuron disease his daily life back The device has helped a man with motor neuron disease communicate and control his computer for nearly two years. By Miryam Naddaf

https://www.nature.com/articles/d41586-026-01863-4?utm_medium=email&_hsenc=p2ANqtz-8rsjVOHX0DxA4fZXKuXaHxkrO24ZOD6jfD4CD8BycAXUrIVsBlEEXUa-oVOYjgEAV5YGdMgq0YP32bo4Sl8k6lwUc76w&_hsmi=139221746&utm_content=139230715&utm_source=hs_email

Switzerland Omics

https://switzerlandomics.ch/technologies/pedigree/?utm_medium=email&_hsenc=p2ANqtz-8PNXn70jjGEPtKSdQXDeohZfEdF7oW5kk9zX3pQ61HHZkJfC8iTStw672Ye1LPW0X_1GH7MGySgItLrilkyLTNniU2nA&_hsmi=139221746&utm_content=139230715&utm_source=hs_email

Scientists improve nearly every aspect of prime editing, moving it closer to treating more genetic diseases The advances in editing efficiency and delivery are important steps toward in vivo therapeutic prime editing. By Leah Eisenstadt

https://www.broadinstitute.org/news/scientists-improve-nearly-every-aspect-prime-editing-moving-it-closer-treating-more-genetic?utm_medium=email&_hsenc=p2ANqtz-_99lzMSM6kfdED6S9u_PjTGsSG4Ezoh9bj2Wo975zvQZ-58dEb6aKatQ-tZg5smRH7KIJSYYzZK7fu_rHKO5SrwZWzYg&_hsmi=139221746&utm_content=139230715&utm_source=hs_email

LifeSciBench: Evaluating Language Models on Realistic, Expert-Level Tasks in the Life Sciences

https://cdn.openai.com/pdf/b4299379-0a97-4ffa-8b9b-c3fbb299caa9/lifescibench_preprint.pdf?utm_medium=email&_hsenc=p2ANqtz-_AY5V0qtmvggGfGqg0uLsTyg12MRDb48nsJM1keqS6T0pDbzf10fTMew9f8TDIV9SC7azeMrZcV4zuNu9sQlZ0LOTs1A&_hsmi=139221746&utm_content=139230715&utm_source=hs_email